The Filing Desk

Omada Health

OMDA · Nasdaq · Health Care · Financials, fiscal 2023 to 2025

OMDA · Last close · November 13, 2026
$14.33
Value Omada Health yourself

Omada Health's revenue rose 53.2% to $260 million in fiscal 2025. Its operating margin was −4.6%, up from −25.7% a year earlier. Free cash flow was $17 million. The diluted share count rose 374.5%.

Omada Health, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 6, 2026 · 0001628280-26-015637 Updated
Revenue
$260M
53.2%
Operating margin
−4.6%
21.1 pts
Net income
−$13M
 
Free cash flow
$17M
 
Return on equity
—
 
Market cap
$962M
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

What Omada Health does

Omada Health provides virtual care between doctor visits for people with long-term health conditions. Its members use a mobile app and connected devices such as scales and blood pressure monitors. They get support from health coaches and other care team staff. Its first program, launched in 2012, aims to prevent diabetes and help with weight. It has since added programs for treating diabetes, high blood pressure and high cholesterol, and for people taking GLP-1 weight-loss drugs.

Omada does not charge members. It sells its programs to organizations that pay for health care: employers, health plans, pharmacy benefit managers (companies that run drug coverage for insurers and employers) and health systems. Some customers contract with Omada directly. Others buy through channel partners that resell the programs to their own customers. At the end of 2025 Omada had more than 2,000 customers and over 886,000 members enrolled in one or more programs. It counts a member as enrolled if billed at least once in the past 12 months.

It says it competes through its clinical rigor, its care model that combines people with technology, and the way its single platform covers several conditions. It says its programs are backed by peer-reviewed research and outside accreditations. Omada has a limited operating history and a history of net losses.

Its biggest risks, as it describes them

  • A limited operating history, fast growth that may be hard to manage, and a history of net losses.
  • Its programs may fail to gain enough market acceptance in a new and changing market.
  • Heavy competition, including from companies with more resources and from new technology.
  • A large part of sales coming from or through a small number of customers and channel partners.
  • Revenue depending on members staying engaged and on its programs showing good health results.
From Omada Health's annual report on Form 10-K, filed March 6, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Omada Health lost money in fiscal 2025: a net loss of $13 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY23FY24FY25
Cash and short-term investments11676222
Debt incl. finance leases—300
Net debt (negative means net cash)—−47−222
Net debt to EBITDA———
Debt to equity——0.0x
Interest coverage−14.0x−9.7x−4.7x
Current ratio—2.1x3.6x
Quick ratio—2.0x3.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Omada Health's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Omada Health says to expect

  • Full year 2026: revenueRevenue in the range of $344 million to $346 million, up from prior guidance of $334 million to $340 million, with the midpoint representing approximately 33% growth compared with 2025.
  • Full year 2026: adjusted EBITDAAdjusted EBITDA in the range of $32 million to $34 million, up from prior guidance of $21 million to $27 million, with the midpoint representing an improvement of approximately $27 million, or roughly five and a half times, compared with 2025.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 5, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

No officer, director or 10% owner of Omada Health reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25
Piotroski F-score——
Rule of 4017.8%59.8%
Altman Z''−13.652.28
Accruals ratio—−13.6%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25
Net income is positive—Fail
Cash from operations is positiveFailPass
Return on assets rose——
Cash from operations exceeds net incomePassPass
Debt fell relative to assets——
Current ratio rose—Pass
Share count didn't riseFailFail
Gross margin rosePassPass
Revenue rose relative to assets——
F-score——
Companies that report no gross profit are scored on the other eight.

Compare

Put Omada Health side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Omada HealthFY2553.2%−4.6%6.5%———
HealthStreamFY254.3%6.7%19.6%———Compare
HeartFlowFY2539.9%−36.4%−33.5%———Compare
CertaraFY258.8%5.0%22.6%0.9%1.1x5Compare
PhreesiaFY2614.5%−1.4%14.1%−2.2%−2.6x6Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

3 years of figures

Fiscal yearFY23FY24FY25
Income statement
Revenue123170260
Revenue growth—38.3%53.2%
Gross profit70103171
Research and development343641
Operating income−66−44−12
Net income−68−47−13
Diluted EPS (US$)−9.52−6.11−0.35
Diluted shares (millions)7837
Cash flow
Cash from operations−50−3418
Capital expenditure011
Free cash flow−50−3517
Dividends paid000
Share buybacks000
Acquisitions000
Stock-based compensation9913
Balance sheet at fiscal year end
Cash and short-term investments11676222
Debt incl. finance leases—300
Total assets—151305
Total liabilities—8676
Shareholders' equity−350−384230
Margins and ratios
Gross margin57.0%60.6%65.7%
Operating margin−53.8%−25.7%−4.6%
Net margin−55.0%−27.8%−4.9%
Free cash flow margin−40.9%−20.5%6.5%
Rule of 40 (growth + FCF margin)—17.8%59.8%
Return on capital———
Return on equity———
Return on assets——−5.6%
Net debt to EBITDA———
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Omada Health's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Omada Health.